LeadIQ logo
Learn more at LeadIQ.com

Insights

Public Offering Mereo BioPharma Group is planning to go public, indicating a potential growth in financial resources and market visibility that can present sales opportunities for partnerships or investment.

Expanded Pipeline With the acquisition of product candidates from Novartis and AstraZeneca, as well as merging with OncoMed to broaden their reach and add oncology programs, Mereo BioPharma has an expanded pipeline offering potential sales opportunities for collaborations or licensing deals.

Updated Clinical Data The release of updated clinical data from studies like the open-label Phase 1b/2 Study of Etigilimab and Nivolumab showcases innovation and progress, presenting potential sales opportunities for pharmaceutical partnerships or further investment.

Strategic Board Appointments Appointing industry experts like Abdul Mullick and Dr. Jacquet to the board of directors brings valuable experience and networks, potentially opening doors for strategic partnerships and collaborations that can drive sales growth.

Focus on Rare Diseases Mereo BioPharma's focus on rare diseases presents a niche market opportunity for sales expansion, attracting specialized partners or investors interested in breakthrough therapies for underserved patient populations.

Similar companies to Mereo BioPharma

Mereo BioPharma Tech Stack

Mereo BioPharma uses 8 technology products and services including Twitter Emoji (Twemoji), Google Font API, Modernizr, and more. Explore Mereo BioPharma's tech stack below.

  • Twitter Emoji (Twemoji)
    Font Scripts
  • Google Font API
    Font Scripts
  • Modernizr
    Javascript Libraries
  • Windows Server
    Operating Systems
  • X-XSS-Protection
    Security
  • HSTS
    Security
  • VMware
    Virtualisation Software
  • Linkedin
    Widgets

Media & News

Mereo BioPharma's Email Address Formats

Mereo BioPharma uses at least 1 format(s):
Mereo BioPharma Email FormatsExamplePercentage
First.Last@mereobiopharma.comJohn.Doe@mereobiopharma.com
78%
FL@mereobiopharma.comJD@mereobiopharma.com
14%
FLast@mereobiopharma.comJDoe@mereobiopharma.com
5%
FiLast@mereobiopharma.comJoDoe@mereobiopharma.com
3%

Frequently Asked Questions

Where is Mereo BioPharma's headquarters located?

Minus sign iconPlus sign icon
Mereo BioPharma's main headquarters is located at 1 Cavendish Place London, W1G 0QF GB. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is Mereo BioPharma's phone number?

Minus sign iconPlus sign icon
You can contact Mereo BioPharma's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Mereo BioPharma's stock symbol?

Minus sign iconPlus sign icon
Mereo BioPharma is a publicly traded company; the company's stock symbol is MREO.

What is Mereo BioPharma's official website and social media links?

Minus sign iconPlus sign icon
Mereo BioPharma's official website is mereobiopharma.com and has social profiles on LinkedIn.

How much revenue does Mereo BioPharma generate?

Minus sign iconPlus sign icon
As of October 2024, Mereo BioPharma's annual revenue reached $15M.

What is Mereo BioPharma's SIC code NAICS code?

Minus sign iconPlus sign icon
Mereo BioPharma's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Mereo BioPharma have currently?

Minus sign iconPlus sign icon
As of October 2024, Mereo BioPharma has approximately 51 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: D. S.Chief Scientific Officer: J. L.Chief Financial Officer: C. F.. Explore Mereo BioPharma's employee directory with LeadIQ.

What industry does Mereo BioPharma belong to?

Minus sign iconPlus sign icon
Mereo BioPharma operates in the Biotechnology Research industry.

What technology does Mereo BioPharma use?

Minus sign iconPlus sign icon
Mereo BioPharma's tech stack includes Twitter Emoji (Twemoji)Google Font APIModernizrWindows ServerX-XSS-ProtectionHSTSVMwareLinkedin.

What is Mereo BioPharma's email format?

Minus sign iconPlus sign icon
Mereo BioPharma's email format typically follows the pattern of . Find more Mereo BioPharma email formats with LeadIQ.

How much funding has Mereo BioPharma raised to date?

Minus sign iconPlus sign icon
As of October 2024, Mereo BioPharma has raised $50M in funding. The last funding round occurred on Jun 14, 2024 for $50M.

When was Mereo BioPharma founded?

Minus sign iconPlus sign icon
Mereo BioPharma was founded in 2015.
Mereo BioPharma

Mereo BioPharma

Biotechnology ResearchLondon, United Kingdom51-200 Employees

Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease.
We are driven by a true understanding of the critical nature of our mission.  We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused and capital efficient manner.
Our journey began back in March 2015 fuelled by the desire to champion high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies.  We acquired three product candidates from Novartis in 2015 and one from AstraZeneca in 2017. Merging with OncoMed in 2019 strengthened our foundation, broadening our reach and adding cutting-edge oncology programs to our pipeline.
The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options.  Mereo’s agile approach is enabling us to move rigorously but quickly through trial programs. We have taken two therapies from in-licensing to pharma through to Phase 3 studies in under 5 years. Our portfolio covers potential therapies addressing critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and two oncology product candidates.
Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across pharma and biotech. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We know what it takes to navigate reimbursement, which can be complex and have the expertise to drive excellence.
Follow our updates on this extraordinary journey as we continue to collaborate with our stakeholders to forge new ways of doing things in rare disease.

Section iconCompany Overview

Headquarters
1 Cavendish Place London, W1G 0QF GB
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
MREO
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
51-200

Section iconFunding & Financials

  • $50M

    Mereo BioPharma has raised a total of $50M of funding over 6 rounds. Their latest funding round was raised on Jun 14, 2024 in the amount of $50M.

  • $10M$50M

    Mereo BioPharma's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $50M

    Mereo BioPharma has raised a total of $50M of funding over 6 rounds. Their latest funding round was raised on Jun 14, 2024 in the amount of $50M.

  • $10M$50M

    Mereo BioPharma's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.